Nomura Research Institute, Ltd.
NURAF · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.53 | 4.97 | 3.30 | 1.03 |
| FCF Yield | 2.88% | 3.77% | 3.69% | 2.07% |
| EV / EBITDA | 15.38 | 15.42 | 11.63 | 18.53 |
| Quality | ||||
| ROIC | 12.87% | 11.24% | 11.78% | 14.64% |
| Gross Margin | 36.00% | 35.44% | 34.65% | 30.38% |
| Cash Conversion Ratio | 0.97 | 1.79 | 1.10 | 1.19 |
| Growth | ||||
| Revenue 3-Year CAGR | 3.38% | 6.39% | 7.94% | 4.98% |
| Free Cash Flow Growth | -12.85% | 44.05% | 15.54% | -26.29% |
| Safety | ||||
| Net Debt / EBITDA | 0.54 | 0.75 | 0.68 | 0.65 |
| Interest Coverage | 23.25 | 18.09 | 20.15 | 30.19 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 82.33 |
| Cash Conversion Cycle | 60.08 | 57.38 | 56.85 | 61.77 |